Mutant p53 drives cancer chemotherapy resistance due to loss of function on activating transcription of PUMA

Autor: Lingling Zhang, Yeying Liu, Guang Luo, Shuaiyu Long, Jing Liu, Nannan Liu, Chuchu Zhang, Yuan Huang, Yingjie Zhang
Jazyk: angličtina
Rok vydání: 2019
Předmět:
0301 basic medicine
Tumor suppressor gene
Transcription
Genetic

Cell Survival
Mutant
Apoptosis
Biology
03 medical and health sciences
0302 clinical medicine
Transcription (biology)
Cyclin-dependent kinase
Loss of Function Mutation
Puma
hemic and lymphatic diseases
Proto-Oncogene Proteins
Humans
Molecular Biology
bcl-2-Associated X Protein
Kinase
Cell Biology
biology.organism_classification
HCT116 Cells
Gene Expression Regulation
Neoplastic

030104 developmental biology
Proto-Oncogene Proteins c-bcl-2
Drug Resistance
Neoplasm

030220 oncology & carcinogenesis
Colonic Neoplasms
Cancer research
biology.protein
Mutant Proteins
biological phenomena
cell phenomena
and immunity

Tumor Suppressor Protein p53
Apoptosis Regulatory Proteins
Platelet-derived growth factor receptor
Developmental Biology
Research Paper
Zdroj: Cell Cycle
Popis: P53 is a critical tumor suppressor gene, activating p53 and its downstream targets to induce apoptosis is a promising way for cancer therapy. However, more than 50% of cancer patients have p53 mutations, which may cause cancer therapy resistance, and the underline mechanism is poorly understood. Here, we found that cell viability decrease and apoptosis induced by p53-dependent traditional drugs in colon cancer cells were eliminated in p53 mutant cells. Mutant p53 did not up-regulate the expression of its direct downstream targets PUMA and p21, due to the inhibition of PUMA transcription. Furthermore, mutant p53 could not bind to the promoter of PUMA to activate its transcription like WT p53 did, while overexpressed WT p53 rescued PUMA-induced subsequent apoptosis. In conclusion, our findings demonstrate mutant p53 may cause chemo-resistance of tumor because of inactivating PUMA transcription, which prompts some new insights for clinical therapy of cancer patients with mutant p53. Abbreviations: CRC: Colorectal cancer; CDKs: Cyclin-dependent kinases; PUMA: p53 up-regulated modulator of apoptosis; PDGF: the platelet-derived growth factor; WT p53: wild-type p53 protein; mutp53: mutant p53 proteins; BAX: Bcl-2-associated X protein; NOXA: Phorbol-12-myristate-13-acetate-induced protein 1.
Databáze: OpenAIRE